Bray Capital Advisors Amgen Inc Transaction History

Bray Capital Advisors

  • $394 Million
  • Q3 2024

A detailed history of Bray Capital Advisors transactions in Amgen Inc stock. As of the latest transaction made, Bray Capital Advisors holds 15,921 shares of AMGN stock, worth $4.17 Million. This represents 1.3% of its overall portfolio holdings.

Number of Shares
15,921
Previous 16,246 2.0%
Holding current value
$4.17 Million
Previous $5.08 Million 1.04%
% of portfolio
1.3%
Previous 1.31%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 01, 2024
SELL
$309.38 - $337.38 $100,548 - $109,648
-325 Reduced 2.0%
15,921 $5.13 Million
Q2 2024

Jul 31, 2024
SELL
$262.75 - $319.31 $23,647 - $28,737
-90 Reduced 0.55%
16,246 $5.08 Million
Q1 2024

Apr 30, 2024
SELL
$268.87 - $324.56 $116,958 - $141,183
-435 Reduced 2.59%
16,336 $4.64 Million
Q4 2023

Jan 29, 2024
BUY
$255.7 - $288.46 $9,205 - $10,384
36 Added 0.22%
16,771 $4.83 Million
Q3 2023

Oct 27, 2023
BUY
$218.65 - $271.46 $34,765 - $43,162
159 Added 0.96%
16,735 $4.5 Million
Q2 2023

Jul 28, 2023
SELL
$214.27 - $253.37 $30,640 - $36,231
-143 Reduced 0.86%
16,576 $3.68 Million
Q1 2023

Apr 28, 2023
SELL
$225.79 - $275.2 $16,256 - $19,814
-72 Reduced 0.43%
16,719 $4.04 Million
Q4 2022

Jan 20, 2023
SELL
$229.03 - $291.01 $318,580 - $404,794
-1,391 Reduced 7.65%
16,791 $0
Q3 2022

Nov 21, 2022
SELL
$224.46 - $253.15 $3,366 - $3,797
-15 Reduced 0.08%
18,182 $4.1 Million
Q2 2022

Aug 01, 2022
BUY
$230.71 - $256.74 $19,610 - $21,822
85 Added 0.47%
18,197 $4.43 Million
Q1 2022

May 03, 2022
SELL
$219.27 - $242.57 $3,069 - $3,395
-14 Reduced 0.08%
18,112 $4.38 Million
Q4 2021

Jan 31, 2022
BUY
$198.88 - $227.6 $46,736 - $53,486
235 Added 1.31%
18,126 $4.08 Million
Q3 2021

Oct 28, 2021
BUY
$212.27 - $248.7 $11,038 - $12,932
52 Added 0.29%
17,891 $3.81 Million
Q2 2021

Jul 28, 2021
BUY
$233.58 - $259.14 $36,204 - $40,166
155 Added 0.88%
17,839 $4.35 Million
Q1 2021

May 03, 2021
BUY
$221.91 - $258.6 $92,758 - $108,094
418 Added 2.42%
17,684 $4.4 Million
Q4 2020

Jan 28, 2021
BUY
$216.38 - $257.67 $130,260 - $155,117
602 Added 3.61%
17,266 $3.97 Million
Q3 2020

Oct 30, 2020
SELL
$234.65 - $260.95 $31,677 - $35,228
-135 Reduced 0.8%
16,664 $4.24 Million
Q2 2020

Jul 28, 2020
SELL
$197.81 - $242.74 $61,914 - $75,977
-313 Reduced 1.83%
16,799 $3.96 Million
Q1 2020

May 01, 2020
SELL
$182.24 - $241.7 $36,265 - $48,098
-199 Reduced 1.15%
17,112 $3.47 Million
Q4 2019

Jan 31, 2020
SELL
$189.21 - $243.2 $62,439 - $80,256
-330 Reduced 1.87%
17,311 $4.17 Million
Q3 2019

Oct 29, 2019
SELL
$174.11 - $208.62 $354,313 - $424,541
-2,035 Reduced 10.34%
17,641 $3.41 Million
Q2 2019

Jul 29, 2019
BUY
$166.7 - $195.41 $340,901 - $399,613
2,045 Added 11.6%
19,676 $3.63 Million
Q1 2019

Apr 30, 2019
BUY
$180.87 - $203.88 $125,523 - $141,492
694 Added 4.1%
17,631 $3.35 Million
Q4 2018

Feb 15, 2019
BUY
$178.4 - $208.25 $43,351 - $50,604
243 Added 1.46%
16,937 $3.3 Million
Q3 2018

Oct 31, 2018
SELL
$185.29 - $208.89 $48,545 - $54,729
-262 Reduced 1.55%
16,694 $3.46 Million
Q2 2018

Jul 31, 2018
SELL
$166.05 - $186.51 $13,616 - $15,293
-82 Reduced 0.48%
16,956 $3.13 Million
Q1 2018

May 04, 2018
SELL
$169.43 - $198.0 $84,715 - $99,000
-500 Reduced 2.85%
17,038 $2.91 Million
Q4 2017

Feb 02, 2018
BUY
$168.79 - $188.59 $5,063 - $5,657
30 Added 0.17%
17,538 $3.05 Million
Q3 2017

Nov 01, 2017
BUY
$167.29 - $191.0 $2.93 Million - $3.34 Million
17,508
17,508 $3.27 Million

Others Institutions Holding AMGN

# of Institutions
3,119
Shares Held
407M
Call Options Held
7.56M
Put Options Held
7.2M
View Full List

About AMGEN INC

AMGN Quotes by TradingView
  • Ticker AMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 534,931,008
  • Market Cap $140B
  • Description
  • Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...
More about AMGN
Track This Portfolio

Track Bray Capital Advisors Portfolio

Follow Bray Capital Advisors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bray Capital Advisors, based on Form 13F filings with the SEC.

News

Stay updated on Bray Capital Advisors with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email